We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Early evidence of immune role in cancer
- Increased cancer in immunocompromised patients
- Immune cells within tumors predict survival
- High dose IL-2 therapy
- Tumor immunity
- Signals in tumor immunity
- Checkpoint inhibition
- CTLA-4 inhibition
- Ipilimumab
- CTLA-4 Ab treatment: immune response criteria
- CTLA-4 toxicity
- CTLA-4 & PD-1
- PD-1 mediated inhibition of T cells
- Nivolumab
- Pembrolizumab
- PD-1 antibody therapy
- CTLA-4 & PD-1: different phases & locations
- Combined therapies
- Combined vs. monotherapy
- Combined vs. monotherapy: adverse events
- The future of immunotherapy in melanoma
- Stage at diagnosis
- Initial presentation in patients who died
- Interferon-alpha-2b
- EORTC 18071
- ECOG 1609
- SWOG 1404
- Potential biomarkers of immune response
- PD-L1 staining
- Mutational load within the tumor
- Mutational load correlates with immune response
- Neo-antigens
- Microbiota & ipilimumab efficacy
- Microbiota & PD-L1 efficacy
- T cells infiltration in tumors
- Tumor phenotypes
- Combination therapy: “Lifting overall survival"
- Immunotherapeutic agents
- Release of cancer cell antigens
- Abscopal effect
- BRAF inhibition therapy
- Immunotherapy + targeted therapy
- Hepatotoxicity on combination therapy
- Cancer antigen presentation
- GM-CSF
- ECOG 1609: adding GM-CSF
- Neoantigens: a paradigm shift for cancer vaccines
- Developing NeoVax
- TVEC (Talimogene Laherparepvec)
- Priming & activation
- Immune modulatory receptors
- Immune checkpoint blockade with IL-2
- Trafficking & infiltration of T cells
- Ipilimumab & bevacizumab
- Recognition & killing of cancer cells
- Indoleamine 2,3 dioxygenase
- Not just melanoma
- Immunotherapy is rapidly changing clinical care
Topics Covered
- Checkpoint inhibition in melanoma
- Immunotherapy in the adjuvant setting
- Biomarkers of immune response
- The future of immunotherapy in melanoma
- Targeting release of cancer antigens
- Targeting cancer antigen presentation
- Targeting priming and activation of the immune system
- Targeting trafficking and infiltration of T-cells
- Targeting recognition and killing of cancer cells
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Buchbinder, E. (2017, February 28). Immune checkpoint blockade in melanoma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 9, 2024, from https://doi.org/10.69645/ZAUF9253.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Elizabeth Buchbinder has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Immunotherapy of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Elizabeth Buchbinder,
and I'm a physician within
the Melanoma Disease Center
at Dana-Farber Cancer Institute,
and an instructor
at Harvard Medical School.
And today,
I'm going to be talking about
Immune Checkpoint Blockade
in Melanoma.
0:15
Immunotherapy has really been
in the news a lot
in the last few years,
in terms of the amazing advances
that have been seen
in the treatment of cancer
through the use of immunotherapy.
However,
some of the earliest efforts
to use the immune system
to battle against cancer,
where in the early 1900s,
when Dr. Coley,
surgeon at the time,
discovered
that some of his patients
who developed
post-operative wound infections
had subsequent responses
in their tumors
and shrinkage of their cancer.
And he attempted to use this
to elicit immune responses
in patients
by causing infections
in their wound and their cancer.
He had some success, however,
in the end it was not
something that caught on,
given the fact that,
many patients got very sick
related to these infections.
However, throughout time,
there have been
spontaneous regressions of cancer
and some felt that a lot of these
are related
to the immune system's function
and immune regulation
of malignancy.
1:18
In addition to evidence
that the immune system
is causing regression in tumors,
there is also evidence
that the immune system can prevent
the development of tumors,
as can be observed in the fact
that transplant patients who are
on strong immunosuppressives
have a much higher risk
of developing malignancy
as compared
to the general population.
And some of the tumors
that are most commonly seen
within these patients
are those tumors that we now know
have a very close relationship
with the immune system
and are tightly regulated by it
such as kidney cancer and melanoma.